

Therapie mit Eisenchelatoren bei chronischen Anämien

- 1) Tanno T, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. *Nature Medicine* 2007;13:1096-101.
- 2) Winder A, et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. *British Journal of Haematology* 2008;142:669-71.
- 3) Bottomley SS. Secondary iron overload disorders. *Seminars in Hematology* 1998;35:77-86.
- 4) Edwards CQ, Skolnick MH, Kushner JP. Coincidental nontransfusional iron overload and thalassemia minor. Association with HLA-linked hemochromatosis. *Blood* 1981;58:844-8.
- 5) Tso SC, Loh TT, Todd D. Iron overload in patients with hemoglobin H disease. *Scandinavian Journal of Haematology* 1984;32:391-4.
- 6) Longo F, et al. The influence of hemochromatosis mutations on iron overload of thalassemia major. *Haematologica* 1999;84:799-803.
- 7) Olivieri NF, Brittenham GM. Iron-chelation therapy and the treatment of thalassaemia. *Blood* 1997;89:739-61.
- 8) Piga A, et al. high dose desferrioxamine as a cause of growth failure in thalassaemic patients. *European Journal of Haematology* 1988;40:380-1.
- 9) Olivieri NF, et al. Growth failure and bony changes induced by deferoxamine. *American Journal of Pediatric Hematology/Oncology* 1992;14:48-56.
- 10) Olivieri NF, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions. *New England Journal of Medicine* 1986;314:869-73.
- 11) Kushner JP, Porter JB, Olivieri NF. Secondary iron overload. *Hematology (Am Soc Hematol Educ Program)* 2001:47-61.
- 12) Fiorelli G, et al. Iron metabolism in thalassemia intermedia. *Haematologica* 1990;75:89-95.
- 13) Brittenham GM, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. *New England Journal of Medicine* 1994;331:567-73.
- 14) Olivieri NF, et al. Survival in medically treated patients with homozygous beta-thalassemia. *New England Journal of Medicine* 1994;331:574-8.
- 15) Adams RJ, et al. Prevention of a first stroke by transfusion in children with sickle-cell anemia and abnormal results on transcranial doppler ultrasonography. *New England Journal of Medicine* 1998;339:5-11.
- 16) DeBaun MR, et al. Epidemiology and treatment of silent infarcts in sickle cell anemia. *Hematology (Am Soc Hematol Educ Program)* 2004:35-40.
- 17) Pegelow CH, et al. Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. *Archives of Neurology* 2001;58:2017-21.
- 18) Platt OS, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. *New England Journal of Medicine* 1994;330:1639-44.
- 19) Harmatz P, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. *Blood* 2000;96:76-9.
- 20) Porter JB, Huehns E. Transfusion and exchange transfusion in sickle cell anaemia, with particular reference to iron metabolism. *Acta Haematologica* 1987;78:198-205.
- 21) Brownell A, Lowson S, Brozovic M. Serum ferritin concentration in sickle crisis. *Journal of Clinical Pathology* 1986;39:253-5.

- 22) De Braekeleer M, et al. Hemochromatosis and pyruvate kinase deficiency. Report of a case and review of the literature. *Annals of Hematology* 1991;1991:188-9.
- 23) Nagai H, et al. An autopsy case of pyruvate kinase deficiency anemia associated with severe hemochromatosis. *Internal Medicine* 1994;33:56-9.
- 24) Zanella A, et al. Iron status in red cell pyruvate kinase deficiency: study of Italian cases. *British Journal of Haematology* 1993;83:485-90.
- 25) Marshall SR, et al. The dangers of iron overload in pyruvate kinase deficiency. *British Journal of Haematology* 2003;120:1090-1.
- 26) Andersen FD, et al. Unexpectedly high but still asymptomatic iron overload in a patient with pyruvate kinase deficiency. *The Hematology Journal* 2004;5:543-5.
- 27) Zanella A, et al. Iron status and HFE genotype in erythrocyte pyruvate kinase deficiency: study of Italian cases. *Blood Cells Mol Dis* 2001;27:653-61.
- 28) Pootrakul P, et al. Serum ferritin levels in thalassemias and the effect of splenectomy. *Acta Haematologica* 1981;66:244-50.
- 29) Parkin JD, et al. Iron absorption after splenectomy in hereditary spherocytosis. *Australian and New Zealand Journal of Medicine* 1974;4:58-61.
- 30) Marks PW, Mitus AJ. Congenital dyserythropoietic anemias. *American Journal of Hematology* 1996;51:55-63.
- 31) Heimpel H. Congenital dyserythropoietic anemias: epidemiology, clinical significance, and progress in understanding their pathogenesis. *Annals of Hematology* 2004;83:613-21.
- 32) Fukuda MN, et al. Incomplete synthesis of N-glycans in congenital dyserythropoietic anemia type II caused by a defect in the gene encoding alpha-mannosidase II. *Proceedings of the National Academy of Sciences of the United States of America* 1990;87:7443-7.
- 33) Fukuda MN. HEMPAS. Hereditary erythroblastic multinuclearity with positive acidified serum lysis test. *Biochimica et Biophysica Acta* 1999;1455:231-9.
- 34) Fukuda MN, et al. Incompletely processed N-glycans of serum glycoproteins in congenital dyserythropoietic anaemia type II (HEMPAS). *British Journal of Haematology* 1992;82:745-52.
- 35) Heimpel H, et al. Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation. *Blood* 2003;102:4576-81.
- 36) Greiner TC, et al. Congenital dyserythropoietic anemia type II diagnosed in a 69-year-old patient with iron overload. *American Journal of Clinical Pathology* 1992;98:522-5.
- 37) Tamura H, et al. A case of congenital dyserythropoietic anemia type II associated with hemochromatosis. *Internal Medicine* 1992;31:380-4.
- 38) Iolascon A, et al. Natural history of congenital dyserythropoietic anemia type II. *Blood* 2001;98:1258-60.
- 39) Wickramasinghe SN, et al. Determinants of iron status and bilirubin levels in congenital dyserythropoietic anaemia type I. *British Journal of Haematology* 1999;107:522-5.
- 40) Hofmann WK, Kaltwasser JP, Hoelzer D. Successful treatment of iron overload by phlebotomies in a patient with congenital dyserythropoietic anemia type II. *Blood* 1997;89:3068-9.
- 41) Pootrakul P, et al. The effect of erythroid hyperplasia on iron balance. *Blood* 1988;71:1124-9.
- 42) Edwards CQ, Skolnick MH, Dadone MM. Iron overload in hereditary spherocytosis: Association with HLA-linked hemochromatosis. *American Journal of Hematology* 1982;13:101-9.
- 43) Mohler DN, Wheby MS. Case report: Hemochromatosis heterozygotes may have significant iron overload when they also have hereditary spherocytosis. *American Journal of the Medical Sciences* 1986;29:320-4.

- 44) O'Mahony S, O'Brien PA, Whelton MJ. Genetic haemochromatosis and congenital spherocytosis. *Lancet* 1987;1:282.
- 45) Barry M, Scheuer PJ, Sherlock S. Hereditary spherocytosis with secondary haemochromatosis. *Lancet* 1968;2:481-5.
- 46) Takegoshi T, et al. An autopsy case of hemochromatosis and hepatoma combined with hereditary spherocytosis. *Japanese Journal of Medicine* 1984;23:48-52.
- 47) Fargion S, et al. Association of hereditary spherocytosis and idiopathic hemochromatosis. *American Journal of Clinical Pathology* 1986;86:645-9.
- 48) Cotter PD, et al. Four new mutations in the erythroid-specific 5-aminolevulinat synthase (ALAS2) gene causing X-linked sideroblastic anemia. Increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. *Blood* 1999;93:1757-69.
- 49) Marcus RE. Iron overload in mild sideroblastic anaemia. *Lancet* 1983;1:1276-7.
- 50) Jensen PD, Jensen IM, Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndromes. *British Journal of Haematology* 1992;80:121-4.
- 51) Jensen PD, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. *British Journal of Haematology* 1996;94:288-99.
- 52) Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). *British Journal of Haematology* 1990;74:45-52.
- 53) Germing U, et al. Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. *British Journal of Haematology* 2000;108:724-8.
- 54) Gattermann N, et al. A heteroplasmic point mutation of mitochondrial tRNA^{Leu}(CUN) in non-lymphoid cell lineages from a patient with acquired idiopathic sideroblastic anaemia. *British Journal of Haematology* 1996;93:845-55.
- 55) Gattermann N, et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. *Blood* 1997;90:4961-72.
- 56) Wulfert M, et al. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. *Experimental Hematology* 2008;36:577-86.
- 57) Cotter PD, et al. Late-onset X-linked sideroblastic anemia. *Journal of Clinical Investigation* 1995;96:2090-6.
- 58) Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. *British Journal of Haematology* 1992;82:358-67.
- 59) Germing U, et al. No increase in age-specific incidence of myelodysplastic syndromes. *Haematologica* 2004;89:905-10.
- 60) Malcovati L, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. *Journal of Clinical Oncology* 2005;23:7594-603.
- 61) Sanz G, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. *Blood* 2008:ASH abstract #640.
- 62) Schafer AI, et al. Clinical consequences of acquired transfusional iron overload in adults. *New England Journal of Medicine* 1981;304:319-24.
- 63) St. Pierre TG, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. *Blood* 2005;105:855-61.
- 64) Modell B, Berdoukas V. *The clinical approach to thalassemia*. New York: Grune and Stratton; 1981.
- 65) Barry M, et al. Long-term chelation therapy in thalassaemia: effect on liver iron concentration, liver histology and clinical progress. *British Medical Journal* 1974;2:16-20.

- 66) Hussain M, et al. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. *Lancet* 1976;2:1278-80.
- 67) Propper R, et al. Continuous subcutaneous administration of deferoxamine B in iron overload. *New England Journal of Medicine* 1976;294:1421-3.
- 68) Pippard MJ, Johnson DK, Finch CA. Ferrioxamine excretion in iron overloaded man. *Blood* 1982;60:288-94.
- 69) Di Gregorio F, et al. An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients. *British Journal of Haematology* 1997;98:601-2.
- 70) Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent deferoxamine. *Journal of Pediatrics* 1997;130:86-8.
- 71) Franchini M, et al. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. *Blood* 2000;95:2776-9.
- 72) Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. *Blood* 2000;95:1229-36.
- 73) Hoffbrand AV, et al. Long-term deferiprone in 51 transfusion-dependent iron overloaded patients. *Blood* 1998;91:295-300.
- 74) Olivieri N, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. *New England Journal of Medicine* 1998;339:417-23.
- 75) Kowdley KV, Kaplan MM. Iron-chelation therapy with oral deferiprone - toxicity or lack of efficacy? *New England Journal of Medicine* 1998;339:468.
- 76) Hoffbrand AV, Cohen A, Hershko O. Role of deferiprone in chelation therapy for transfusional iron overload. *Blood* 2003;102:17-24.
- 77) Ceci A, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. *British Journal of Haematology* 2002;118:330.
- 78) Anderson LJ, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. *Lancet* 2002;360:516-20.
- 79) Cohen AR, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. *Blood* 2003;102:1583-7.
- 80) Voskaridou E, et al. Deferiprone as an oral iron chelator in sickle cell disease. *Annals of Hematology* 2005;in press?
- 81) Wanless IR, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. *Blood* 2002;100:1566-9.
- 82) Mourad FH, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. *British Journal of Haematology* 2003;121:187-9.
- 83) D'Angelo E, et al. Combined therapy with desferrioxamine and deferiprone: a new protocol for iron chelation in thalassemia. *Journal of Pediatric Hematology/Oncology* 2004;26:451-3.
- 84) Wu KH, et al. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with b-thalassaemia major. *Annals of Hematology* 2004;83:471-3.
- 85) Alymara V, et al. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. *The Hematology Journal* 2004;5:475-9.
- 86) Kattamis A, et al. Iron chelation treatment with combined therapy with deferiprone and deferoxamine: a 12-month trial. *Blood Cells and Molecular Disease* 2006;36:21-5.
- 87) Gattermann N, Musch A. Deferasirox. Orale Therapie bei transfusionsbedingter Eisenüberladung. *Arzneimitteltherapie* 2007;25:240-7.

- 88) Cappellini MD, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. *Blood* 2005;107:3455-62.
- 89) Porter J, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anemias to deferasirox (ICL670): a 1-yr prospective study. *European Journal of Haematology* 2008;80:168-76.
- 90) List A, et al. Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes. *Blood* 2008:ASH abstract #634.
- 91) Gattermann N, et al. Efficacy and safety of deferasirox (Exjade) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial. *Blood* 2008:ASH abstract #633.
- 92) Cappellini MD, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. *Blood* 2006;107:3455-62.
- 93) Nathan DG. Oral iron chelation: new drug, old rules. *Blood* 2008;111:483-4.